Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

21 Citations (Scopus)

Original language	English
Journal	The New England journal of medicine
Volume	375
Issue number	21
Pages (from-to)	2101-2102
Number of pages	2
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMc1610828#SA1
Publication status	Published - 24 Nov 2016

Keywords

@article{e33a0073f3a941c7a103cbcb057576e0,

title = "Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis",

keywords = "Humans, Psoriasis, Severity of Illness Index, Treatment Outcome, Letter",

author = "Alexander Egeberg",

year = "2016",

month = nov,

day = "24",

doi = "10.1056/NEJMc1610828#SA1",

language = "English",

volume = "375",

pages = "2101--2102",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "21",

}

TY - JOUR

T1 - Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

AU - Egeberg, Alexander

PY - 2016/11/24

Y1 - 2016/11/24

KW - Humans

KW - Psoriasis

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Letter

U2 - 10.1056/NEJMc1610828#SA1

DO - 10.1056/NEJMc1610828#SA1

M3 - Journal article

C2 - 27959739

VL - 375

SP - 2101

EP - 2102

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -